Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT ID: NCT04918186
Last Updated: 2025-09-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-05-03
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800
Fallopian Tube Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Platinum-Refractory Fallopian Tube Carcinoma
+47 more
ACTIVE_NOT_RECRUITING
PHASE2
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
NCT02659384
Ovarian Neoplasms
COMPLETED
PHASE2
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
NCT02431559
Ovarian Cancer
COMPLETED
PHASE1/PHASE2
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
NCT00610714
Ovarian Neoplasms
Ovarian Cancer
COMPLETED
PHASE2
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
NCT03598270
Recurrent Ovarian Carcinoma
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Ovarian Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Durvalumab + BA3011 (Arm Closed)
Group Type
EXPERIMENTAL
Durvalumab
Intervention Type
DRUG
1500mg IV, 60 min day 1 every 4 weeks
BA3011
Intervention Type
DRUG
IV
Durvalumab + BA3021 (Arm Closed)
Group Type
EXPERIMENTAL
Durvalumab
Intervention Type
DRUG
1500mg IV, 60 min day 1 every 4 weeks
BA3021
Intervention Type
DRUG
IV
ENB-003 + Toripalimab
Group Type
EXPERIMENTAL
ENB003
Intervention Type
DRUG
IV
Toripalimab
Intervention Type
DRUG
IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Durvalumab
1500mg IV, 60 min day 1 every 4 weeks
Intervention Type
DRUG
BA3011
IV
Intervention Type
DRUG
BA3021
IV
Intervention Type
DRUG
ENB003
IV
Intervention Type
DRUG
Toripalimab
IV
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* This study will enroll women with platinum resistant high grade serous ovarian cancer.
* This study is open to minorities as appropriate but is not designed to measure differences in intervention effects.
* All patients must be registered for screening prior to study enrollment, however, if biomarker testing results are not required prior to enrollment to a substudy, then enrollment can proceed immediately. CCTG will advise sites when biomarker testing results are required prior to substudy enrollment.
Additional Criteria To Be Met Prior To Sub-study Enrollment All patients must fulfill all of the following criteria to be eligible for enrollment to the study. Additional eligibility criteria and relevant timings that are specific to a substudy are listed in each substudy specific protocol.
* Patients must have platinum resistant high grade serous carcinoma of ovarian, fallopian tube or peritoneal origin defined as progression within 6 months of last platinum containing chemotherapy. Histological confirmation of the original primary tumour is required.
* All patients must have measurable disease as defined by RECIST 1.1. The criteria for defining measurable disease are as follows:
* Chest x-ray ≥ 20 mm
* CT scan (with slice thickness of 5 mm) ≥ 10 mm - longest diameter
* Physical exam (using calipers) ≥ 10 mm
* Lymph nodes by CT scan ≥ 15 mm - measured in short axis
* Patients must have at least one disease site amendable to pre and on-treatment biopsies and must consent to undergo these tumour biopsies.
* Prior surgery is permitted provided that a minimum of at least 28 days have elapsed between any major surgical procedure and date of enrollment, and that wound healing has occurred.
* Systemic Therapy:
* There is no limit to the number of prior regimens for platinum-sensitive disease. However, patients may not have received more than one cytotoxic chemotherapy regimen for platinum-resistant disease.
* Patients may have received non-cytotoxic therapies (excluding agents targeted by the planned substudy). Refer to each substudy protocol for exclusions.
* Prior treatment with an immune checkpoint inhibitor (ICI) is permissible providing the ICI was not discontinued for severe or recurrent severe toxicity (including myocarditis, or other myocardiotoxicity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyper thyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis/polymyositis, hepatitis, nephritis, Type 1 diabetes, thrombocytopenia)
* A minimum of 4 weeks must have elapsed between last dose of prior therapy and enrollment.
* All reversible prior toxicity must have recovered to grade ≤ 1 (consult CCTG in the case of irreversible toxicity)
* Other Therapy:
• Radiation, endocrine therapy, or other non-anti-cancer investigational agents are permitted provided a minimum of 28 days (4 weeks) have elapsed between the last dose and enrollment. Exceptions may be made for low-dose, non-myelosuppressive radiotherapy after consultation with CCTG.
* ECOG performance status 0 or 1 and have a life expectancy ≥ 3 months.
* Patients must be ≥ 18 years of age.
* All patients must have consented to:
1. Release of tumour block from their primary or metastatic tumour, if available. If archival tissue is unavailable, a tumour biopsy is required during screening. The centre/pathologist must have agreed to the submission of the specimen(s).
2. Pre and on treatment tumour biopsies:
* Core needle (a minimum of 6 core samples are required) or excisional biopsies or resected tissue specimens are required.
* CCTG will advise sites when biomarker testing results are required prior to enrollment
* Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the trial.
* Patients must have adequate organ and marrow function measured within 7 days prior to enrollment including;
* Absolute neutrophils ≥ 1.5 x 10\^9/L (1500/µL)
* Platelets ≥ 100 x 10\^9/L (100 x 103/µL)
* Hemoglobin ≥90g/L\* (10.0 g/dL) with no blood transfusions in the past 28 days.
* Bilirubin ≤ 1.5 x ULN (upper limit of normal)\*\*
* AST \& ALT ≤ 2.5 x ULN; if patient has liver metastases ≤ 5.0 x ULN
* Serum creatinine or: Creatinine clearance ≤ 1.5 x ULN / \>50 mL/min
* Albumin \>35 g/L (3.5 g/dL)
* INR/PTT INR \< 1.7 or PTT \< 4 seconds above control
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Patients must be accessible for treatment and follow up. Patients enrolled on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.
* Patient must agree to return to their primary care facility for any adverse events, response assessments and follow-up, which may occur through the course of the trial.
* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient enrollment.
* Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation
* This study is open to minorities as appropriate but is not designed to measure differences in intervention effects.
* All patients must be registered for screening prior to study enrollment, however, if biomarker testing results are not required prior to enrollment to a substudy, then enrollment can proceed immediately. CCTG will advise sites when biomarker testing results are required prior to substudy enrollment.
Additional Criteria To Be Met Prior To Sub-study Enrollment All patients must fulfill all of the following criteria to be eligible for enrollment to the study. Additional eligibility criteria and relevant timings that are specific to a substudy are listed in each substudy specific protocol.
* Patients must have platinum resistant high grade serous carcinoma of ovarian, fallopian tube or peritoneal origin defined as progression within 6 months of last platinum containing chemotherapy. Histological confirmation of the original primary tumour is required.
* All patients must have measurable disease as defined by RECIST 1.1. The criteria for defining measurable disease are as follows:
* Chest x-ray ≥ 20 mm
* CT scan (with slice thickness of 5 mm) ≥ 10 mm - longest diameter
* Physical exam (using calipers) ≥ 10 mm
* Lymph nodes by CT scan ≥ 15 mm - measured in short axis
* Patients must have at least one disease site amendable to pre and on-treatment biopsies and must consent to undergo these tumour biopsies.
* Prior surgery is permitted provided that a minimum of at least 28 days have elapsed between any major surgical procedure and date of enrollment, and that wound healing has occurred.
* Systemic Therapy:
* There is no limit to the number of prior regimens for platinum-sensitive disease. However, patients may not have received more than one cytotoxic chemotherapy regimen for platinum-resistant disease.
* Patients may have received non-cytotoxic therapies (excluding agents targeted by the planned substudy). Refer to each substudy protocol for exclusions.
* Prior treatment with an immune checkpoint inhibitor (ICI) is permissible providing the ICI was not discontinued for severe or recurrent severe toxicity (including myocarditis, or other myocardiotoxicity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyper thyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis/polymyositis, hepatitis, nephritis, Type 1 diabetes, thrombocytopenia)
* A minimum of 4 weeks must have elapsed between last dose of prior therapy and enrollment.
* All reversible prior toxicity must have recovered to grade ≤ 1 (consult CCTG in the case of irreversible toxicity)
* Other Therapy:
• Radiation, endocrine therapy, or other non-anti-cancer investigational agents are permitted provided a minimum of 28 days (4 weeks) have elapsed between the last dose and enrollment. Exceptions may be made for low-dose, non-myelosuppressive radiotherapy after consultation with CCTG.
* ECOG performance status 0 or 1 and have a life expectancy ≥ 3 months.
* Patients must be ≥ 18 years of age.
* All patients must have consented to:
1. Release of tumour block from their primary or metastatic tumour, if available. If archival tissue is unavailable, a tumour biopsy is required during screening. The centre/pathologist must have agreed to the submission of the specimen(s).
2. Pre and on treatment tumour biopsies:
* Core needle (a minimum of 6 core samples are required) or excisional biopsies or resected tissue specimens are required.
* CCTG will advise sites when biomarker testing results are required prior to enrollment
* Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the trial.
* Patients must have adequate organ and marrow function measured within 7 days prior to enrollment including;
* Absolute neutrophils ≥ 1.5 x 10\^9/L (1500/µL)
* Platelets ≥ 100 x 10\^9/L (100 x 103/µL)
* Hemoglobin ≥90g/L\* (10.0 g/dL) with no blood transfusions in the past 28 days.
* Bilirubin ≤ 1.5 x ULN (upper limit of normal)\*\*
* AST \& ALT ≤ 2.5 x ULN; if patient has liver metastases ≤ 5.0 x ULN
* Serum creatinine or: Creatinine clearance ≤ 1.5 x ULN / \>50 mL/min
* Albumin \>35 g/L (3.5 g/dL)
* INR/PTT INR \< 1.7 or PTT \< 4 seconds above control
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Patients must be accessible for treatment and follow up. Patients enrolled on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.
* Patient must agree to return to their primary care facility for any adverse events, response assessments and follow-up, which may occur through the course of the trial.
* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient enrollment.
* Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation
Exclusion Criteria
* Patients with a history of other malignancy may be eligible if curatively treated and/or the malignancy does not affect the determination of safety or efficacy of the investigational regimen (must be confirmed with CCTG prior to enrollment).
* Patients with uncontrolled or serious illnesses, or medical conditions which could cause unacceptable safety risks or would not permit the patient to be managed according to the protocol or substudy. This includes but is not limited to:
* history of intra-abdominal abscess within 3 months prior to starting treatment;
* other active infection or chronic liver disease requiring systemic therapy;
* active or known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection on antiviral treatment or with detectable viral load;
* history of interstitial lung disease, non-infectious pneumonitis or severe pulmonary disease exacerbated by pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung disease, etc.
* clinically significant pleural, pericardial, and/or peritoneal effusion (e.g., effusion affecting normal organ function and/or requiring percutaneous drainage or diuretic control);
* autoimmune disease requiring chronic steroid use;
* prior history of a stroke or transient ischemic attack within the last 6 months;
* history of significant cardiac disease within 6 months prior to starting treatment such as myocardial infarction, unstable angina, cardiomyopathy, congestive heart failure;
* prior allogeneic stem cell transplantation or organ transplantation.
* Central nervous system metastases
* Symptomatic uncontrolled brain metastases requiring corticosteroid treatment.
* History of spinal cord compression unless after definitive treatment the patient has clinically stable disease (SD) for at least 28 days prior to starting investigational agent(s).
* Pregnant or lactating (breastfeeding) women.
* Patients receiving concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents.
* Active or prior documented autoimmune or inflammatory disorders, including: inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea, systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment.
* Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune conditions only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions considered to be of low risk for recurrence are permitted to enroll.
* Patients must not have been administered a live vaccine ≤ 4 weeks before enrollment.
Note: Seasonal vaccines for influenza are general inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and not allowed.
* QTc (using the Fridericia correction calculation) \>470 msec or \>450 msec if history of additional risk factors for Torsade de Pointe (e.g. heart failure, hypokalemia, family history of Long QT Syndrome) or use of concomitant medications that prolong the QT/QTc interval.
* Patients with uncontrolled or serious illnesses, or medical conditions which could cause unacceptable safety risks or would not permit the patient to be managed according to the protocol or substudy. This includes but is not limited to:
* history of intra-abdominal abscess within 3 months prior to starting treatment;
* other active infection or chronic liver disease requiring systemic therapy;
* active or known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection on antiviral treatment or with detectable viral load;
* history of interstitial lung disease, non-infectious pneumonitis or severe pulmonary disease exacerbated by pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung disease, etc.
* clinically significant pleural, pericardial, and/or peritoneal effusion (e.g., effusion affecting normal organ function and/or requiring percutaneous drainage or diuretic control);
* autoimmune disease requiring chronic steroid use;
* prior history of a stroke or transient ischemic attack within the last 6 months;
* history of significant cardiac disease within 6 months prior to starting treatment such as myocardial infarction, unstable angina, cardiomyopathy, congestive heart failure;
* prior allogeneic stem cell transplantation or organ transplantation.
* Central nervous system metastases
* Symptomatic uncontrolled brain metastases requiring corticosteroid treatment.
* History of spinal cord compression unless after definitive treatment the patient has clinically stable disease (SD) for at least 28 days prior to starting investigational agent(s).
* Pregnant or lactating (breastfeeding) women.
* Patients receiving concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents.
* Active or prior documented autoimmune or inflammatory disorders, including: inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea, systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment.
* Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune conditions only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions considered to be of low risk for recurrence are permitted to enroll.
* Patients must not have been administered a live vaccine ≤ 4 weeks before enrollment.
Note: Seasonal vaccines for influenza are general inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and not allowed.
* QTc (using the Fridericia correction calculation) \>470 msec or \>450 msec if history of additional risk factors for Torsade de Pointe (e.g. heart failure, hypokalemia, family history of Long QT Syndrome) or use of concomitant medications that prolong the QT/QTc interval.
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Research Institute, New York City
OTHER
Sponsor Role
collaborator
AstraZeneca
INDUSTRY
Sponsor Role
collaborator
BioAtla, Inc.
INDUSTRY
Sponsor Role
collaborator
Canadian Cancer Trials Group
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen MacKay
Role: STUDY_CHAIR
Sunnybrook Health Sciences Centre, Toronto, Ontario Canada
Anna Tinker
Role: STUDY_CHAIR
BCCA - Vancouver Cancer Centre, BC Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Chicago Medical Center
Chicago, Illinois, United States
Site Status
RECRUITING
BCCA - Kelowna
Kelowna, British Columbia, Canada
Site Status
RECRUITING
BCCA - Vancouver
Vancouver, British Columbia, Canada
Site Status
RECRUITING
Odette Cancer Centre
Toronto, Ontario, Canada
Site Status
RECRUITING
University Health Network
Toronto, Ontario, Canada
Site Status
RECRUITING
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
Site Status
NOT_YET_RECRUITING
The Jewish General Hospital
Montreal, Quebec, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
John Moroney
Role: primary
773-834-4732
Susan Ellard
Role: primary
250 712-3900 ext. 686657
Anna Tinker
Role: primary
604 877-6000 ext. 2707
Helen MacKay
Role: primary
416 480-5145
Stephanie Lheureux
Role: primary
416 946-4501 ext. 2415
Diane Provencher
Role: primary
514 890-8444
Susie K.S. Lau
Role: primary
514 340-8222 ext. 3114
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
NCT02915523
COMPLETED
PHASE1/PHASE2
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
NCT03117933
COMPLETED
PHASE2
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
NCT03249142
COMPLETED
PHASE1/PHASE2
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
NCT00390611
COMPLETED
PHASE2
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809
RECRUITING
PHASE3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
NCT07213804
RECRUITING
PHASE3
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
NCT00753545
COMPLETED
PHASE2
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
NCT03353831
COMPLETED
PHASE3
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
NCT01248949
COMPLETED
PHASE1
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
NCT02726997
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00951496
COMPLETED
PHASE3
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01074411
COMPLETED
PHASE1
CT-2106 for the Second Line Treatment of Ovarian Cancer
NCT00291837
COMPLETED
PHASE2
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
NCT05116189
ACTIVE_NOT_RECRUITING
PHASE3
Carboplatin-cyclophosphamide Combined With Atezolizumab
NCT02914470
COMPLETED
PHASE1
An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
NCT00532194
UNKNOWN
PHASE3
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
NCT02983799
COMPLETED
PHASE2
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03206047
COMPLETED
PHASE1/PHASE2
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04019288
TERMINATED
PHASE1/PHASE2
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03113487
ACTIVE_NOT_RECRUITING
PHASE2
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01459380
COMPLETED
PHASE1
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
NCT03704467
COMPLETED
PHASE1
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
NCT01650376
UNKNOWN
PHASE1/PHASE2